BIOSENTA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.335 CAD | 0.00% |
|
-25.56% | +52.27% |
| Apr. 19 | Biosenta Inc. announced that it expects to receive CAD 0.6 million in funding | CI |
| Mar. 27 | Biosenta Inc. Announces Successful Launch of Bench Scale Production Plant | CI |
Valuation
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1.758 | 0.9844 | 4.856 | 10.27 | 9.216 | 11.09 |
| Enterprise Value (EV) 1 | 2.031 | 1.592 | 5.606 | 11.37 | 10.82 | 16.7 |
| P/E ratio | -1.38 x | -1.86 x | -5.88 x | -4.62 x | -5.84 x | -1.74 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1,506 x | - | 3,174 x | 61.1 x | 8,007 x | 10,644 x |
| EV / Revenue | 1,740 x | - | 3,664 x | 67.6 x | 9,397 x | 16,030 x |
| EV / EBITDA | -8.33 x | -3.27 x | - | - | - | - |
| EV / FCF | -7.08 x | -13.3 x | -32.4 x | 924 x | -11.2 x | 140 x |
| FCF Yield | -14.1% | -7.49% | -3.08% | 0.11% | -8.89% | 0.71% |
| Price to Book | -1.94 x | -0.69 x | -2.6 x | -3.96 x | -3.15 x | -1.41 x |
| Nbr of stocks (in thousands) | 14,063 | 14,063 | 17,342 | 19,381 | 23,040 | 26,407 |
| Reference price 2 | 0.1250 | 0.0700 | 0.2800 | 0.5300 | 0.4000 | 0.4200 |
| Announcement Date | 7/30/19 | 1/28/20 | 1/28/21 | 1/27/22 | 1/27/23 | 1/29/24 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.001167 | - | 0.00153 | 0.1681 | 0.001151 | 0.001042 |
| EBITDA 1 | -0.2438 | -0.4872 | - | - | - | - |
| EBIT 1 | -0.2444 | -0.4878 | -0.7045 | -2.008 | -1.218 | -1.483 |
| Operating Margin | -20,942.93% | - | -46,046.34% | -1,194.37% | -105,790.62% | -142,275.24% |
| Earnings before Tax (EBT) 1 | -1.19 | -0.5301 | -0.7619 | -2.042 | -1.458 | -6.3 |
| Net income 1 | -1.19 | -0.5301 | -0.7619 | -2.042 | -1.458 | -6.3 |
| Net margin | -101,940.53% | - | -49,797.91% | -1,214.64% | -126,695.13% | -604,582.92% |
| EPS 2 | -0.0904 | -0.0377 | -0.0476 | -0.1147 | -0.0685 | -0.2409 |
| Free Cash Flow 1 | -0.287 | -0.1193 | -0.1728 | 0.0123 | -0.9616 | 0.1194 |
| FCF margin | -24,594.34% | - | -11,295.23% | 7.32% | -83,543.87% | 11,459.6% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 7/30/19 | 1/28/20 | 1/28/21 | 1/27/22 | 1/27/23 | 1/29/24 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.27 | 0.61 | 0.75 | 1.1 | 1.6 | 5.61 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -1.119 x | -1.247 x | - | - | - | - |
| Free Cash Flow 1 | -0.29 | -0.12 | -0.17 | 0.01 | -0.96 | 0.12 |
| ROE (net income / shareholders' equity) | 361% | 45.3% | 46.1% | 91.5% | 52.9% | 117% |
| ROA (Net income/ Total Assets) | -18.8% | -1,626% | -686% | -674% | -293% | -501% |
| Assets 1 | 6.345 | 0.0326 | 0.1111 | 0.3031 | 0.498 | 1.256 |
| Book Value Per Share 2 | -0.0600 | -0.1000 | -0.1100 | -0.1300 | -0.1300 | -0.3000 |
| Cash Flow per Share 2 | 0 | 0 | 0 | 0.0100 | 0 | 0 |
| Capex | - | - | - | - | - | 0.02 |
| Capex / Sales | - | - | - | - | - | 1,493.19% |
| Announcement Date | 7/30/19 | 1/28/20 | 1/28/21 | 1/27/22 | 1/27/23 | 1/29/24 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +52.27% | 7.25M | |
| -18.39% | 38.86B | |
| +12.44% | 25.93B | |
| -26.63% | 6.09B | |
| +6.04% | 5.98B | |
| -5.67% | 3.06B | |
| +5.20% | 2.42B | |
| -12.14% | 1.85B | |
| +27.19% | 936M | |
| -4.16% | 618M |
- Stock Market
- Equities
- ZRO Stock
- Financials Biosenta Inc.
